Abstract:Background: Nitric oxide has prosurvival effects that can limit ischemia-reperfusion injuries. However, the matrix glycoprotein thrombospondin-1 is induced following ischemia-reperfusion injury and limits nitric oxide signaling by engaging its cell surface receptor CD47. In this article, the authors examine whether postinjury blocking of this inhibitory signal can protect from ischemia-reperfusion injury in a rat flap model. Methods: A total of 40 tissue flaps were created in rats based solely on the deep inferior epigastric vessels. Microvascular clamps were used to create 45 minutes of ischemia time to the flaps. The flaps were then treated using a monoclonal antibody to CD47 or an isotype-matched control immunoglobulin G1 5 or 30 minutes after clamp removal. Twenty-four or 72 hours postoperatively, the necrotic area of the flap was determined, and serum, deep inferior epigastric vessels, and flaps were harvested for analysis from five rats in each respective group. Results: Treatment with a CD47 antibody 5 minutes after reperfusion significantly reduces flap necrosis compared with immunoglobulin G1 control (9 percent versus 43 percent; p < 0.01). The protective effect is even more dramatic when treatment is delayed until 30 minutes after reperfusion (10 percent versus 88 percent for control; p < 0.01). Markers of neutrophil and endothelial cell activation along with total leukocytes are reduced in CD47 antibody-treated flaps, as are tissue malondialdehyde levels. Levels of cyclic guanosine monophosphate are elevated 72 hours postoperatively in the CD47 antibody-treated deep inferior epigastric vessels versus the control flaps. Conclusions: Therapies targeting the thrombospondin-1 receptor CD47 offer potential for increasing tissue survival in ischemia-reperfusion injuries. The ability to protect when given after ischemia-reperfusion injury enables a broader clinical applicability.

Protective effect of artificially induced hibernation against lethal doses of whole body x-irradiation in CF male mice.

CD47 blockade reduces ischemia-reperfusion injury and improves outcomes in a rat kidney transplant model

Anti‐CD47 monoclonal antibody therapy reduces ischemia‐reperfusion injury of renal allografts in a porcine model of donation after cardiac death

Solvatochromic Coatings with Self-Cleaning Property from Palygorskite@Polysiloxane/Crystal Violet Lactone.

Problem solving with pentagons: Tsai-type quasicrystal as a structural response to chemical pressure.

Activation of parenchymal CD47 promotes renal ischemia-reperfusion injury

Ex Vivo Anchored PD‐L1 Functionally Prevent in Vivo Renal Allograft Rejection

Myoepithelial hamartoma of the ileum causing intussusception.

Attenuation of Ischemia-Reperfusion Injury and Improvement of Survival in Recipients of Steatotic Rat Livers Using CD47 Monoclonal Antibody

The role of CD47 in pathogenesis and treatment of renal ischemia reperfusion injury

New directions in type 2 diabetes mellitus: an update of current oral antidiabetic therapy.

Thrombospondin-1/CD47 blockade following ischemia-reperfusion injury is tissue protective

Intraorbital epidermoid cyst: a 5-year-old with exophthalmos and strabismus.

[Neoadjuvant chemotherapy with tegafur suppository for rectal cancer--effects of tegafur on nuclear DNA content of cancer cells--Tochigi Colorectal Cancer Study Group].

A broadband angled-dipole array antenna with radom

The effects of cell surface CD47 downregulation on ischaemia-reperfusion injury during pig liver transplantation

Pharmacologic targeting of renal ischemia-reperfusion injury using a normothermic machine perfusion platform

Abo-Incompatible Living Kidney Transplantation

Big Data Based Analysis Framework for Product Manufacturing and Maintenance Process

[Apropos of histamine liberating properties of colistin].

CD14 blockade to prevent ischemic injury to donor organs